(1 - 9 from 9
)
Phase 3 Trial on Prostate Cancer Imaging Agent Doses 1st ...
prostatecancernewstoday.com
Dec 12, · This valuable information has the potential to provide earlier diagnoses, more informed treatment decisions, the ability to monitor responses, and ultimately improve patient outcomes,” Lawrence Saperstein, MD, assistant professor of radiology and biomedical imaging and chief of nuclear medicine at the Yale Smilow Cancer Hospital, and the ...
Progenics Doses First Patient in Pivotal Phase 3 Study of ...
www.globenewswire.com
Dec 03, · Dr. Lawrence Saperstein, Assistant Professor of Radiology and Biomedical Imaging and Chief of Nuclear Medicine at Yale Smilow Cancer Hospital, and a …
sorted by relevance / date